Advances in Bioresearch
Adv. Biores., Vol 15 (2) March 2024:26-32

Print ISSN 0976-4585; Online ISSN 2277-1573
Journal's URL:http://www.soeagra.com/abr.html
CODEN: ABRDC3
DOI: 10.15515/abr.0976-4585.15.2.2632

Advances in Bioresearch

REVIEW ARTICLE

Advances in Targeted Therapies for Hematologic Malignancies: A Review of Novel Agents

[1]Anand Guddur, [2]Rashmi Gudur [3]V. C. Patil and [4]Ajinkya Bahulekar
[1-2]Department of Oncology Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, Karad, Maharashtra
[3-4]Department of General Medicine Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth Deemed To Be University, Karad

ABSTRACT
Because targeted treatments explicitly target the molecular defects that drive the growth of cancer, they have completely changed the landscape of treatment for hematologic malignancies. The causes, clinical results, difficulties, new approaches, and prospects for newer drugs in hematologic oncology are all thoroughly examined in this study. Targeted treatments work by selectively delivering cytotoxic drugs, inhibiting aberrant signalling pathways, and modifying immune responses. Significant gains in clinical outcomes, including as extended progression-free survival and improved overall survival in a range of hematologic malignancies, have resulted from these tactics. Targeted medicines' full potential is hampered by issues including acquired resistance, off-target effects, heterogeneity of responses, and accessibility. Innovative methods, including as combination therapy, biomarker-driven tactics, and better drug design, are needed to overcome these obstacles. Novel immunotherapies, antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell treatment, small molecule inhibitors, and other emerging therapeutic approaches present intriguing directions for future interventions. The future of hematologic cancer therapy will also be shaped by developments in precision medicine, conquering resistance mechanisms, and using cutting-edge technology like gene editing and artificial intelligence. This thorough analysis sheds light on the state of the field, obstacles to overcome, and future developments in targeted treatments for hematologic malignancies.
Keywords: *Targeted therapies, Hematologic malignancies, Mechanisms, Clinical outcomes, Future directions*

Received 20.01.2023 Revised 01.03.2023 Accepted 21.03.2024

How to cite this article:
Anand G, Rashmi G, V. C. Patil and Ajinkya B. Advances in Targeted Therapies for Hematologic Malignancies: A Review of Novel Agents. Adv. Biores., Vol 15 (2) March 2024:26-32

INTRODUCTION

With the introduction of targeted medicines, the field of oncology has seen a paradigm change in the treatment of hematologic malignancies. The therapy landscape has been completely transformed by these innovative therapeutic methods, which are specially tailored to disrupt aberrant molecular pathways that propel the spread of cancer [1]. Hematologic malignancies comprise a diverse range of tumours that impact the lymphatic system, bone marrow, and blood, such as myelomas, lymphomas, and leukaemias [2]. In the past, traditional medicines like radiation and chemotherapy were the mainstay of treatment plans for these cancers. These medications had significant side effects and had limited specificity [3].

A new age in cancer therapy has been ushered in by the development of targeted medicines, which are based on a better knowledge of the molecular and genetic changes that propel the growth of cancer [4]. By targeting the unique weaknesses of cancer cells and protecting healthy cells at the same time, these treatments seek to maximise benefits and reduce side effects [5]. Notably, by directly targeting the underlying genetic aberrations driving oncogenesis, targeted treatments have demonstrated great efficacy in treating hematologic malignancies [6].

The identification of important genetic alterations, dysregulated signalling pathways, and overexpressed proteins that are ideal targets for these cutting-edge treatments has been made possible by significant advancements in genomic profiling and molecular diagnostics [7]. Tyrosine kinase inhibitors (TKIs) that target the BCR-ABL fusion gene, for example, were developed as a result of the discovery of the BCR-ABL

fusion gene in chronic myeloid leukaemia (CML), which has had a revolutionary effect on the treatment of CML [8].

Targeted treatments comprise a range of techniques, including as gene therapies, immunotherapies, small molecule inhibitors, and monoclonal antibodies, all of which are intended to selectively disrupt certain biological targets or pathways [9]. The effective targeting of malignant B cell surface antigens by monoclonal antibodies, including rituximab and alemtuzumab, has been demonstrated [10]. This leads to immune-mediated cytotoxicity. The results of B-cell lymphomas treated with these antibodies have improved noticeably, demonstrating the promise of targeted immunotherapies for hematologic malignancies.

Furthermore, the way that small molecule inhibitors work is by interfering with intracellular signalling cascades that are vital to the survival and growth of cancer cells. Examples of these medications include imatinib and ibrutinib [1]. Because these targeted medicines precisely inhibit critical kinases or enzymes implicated in neoplastic pathways, they have shown significant therapeutic improvements in a variety of hematologic malignancies.

The development of targeted therapeutics has not only changed the course of cancer therapy but also had an impact on the idea of precision medicine [2]. Customised therapy strategies, based on each patient's unique molecular profile, have become a viable option for maximising therapeutic benefits and reducing side effects associated with treatment [3].

Targeted medicines have been incredibly successful, yet problems still exist, such as acquired resistance, patient variability in response, and the advent of novel resistance mechanisms [4]. The necessity for ongoing research efforts to get beyond these obstacles is highlighted by the development of resistance to targeted treatments, which is frequently linked to genetic abnormalities or adaptive changes in cancer cells [5].

To sum up, the emergence of targeted medicines heralds a revolutionary period in the treatment of hematologic malignancies, providing fresh opportunities for enhanced therapeutic effectiveness and better patient outcomes. In the context of hematologic malignancies, this review seeks to go further into the mechanisms, targets, clinical results, difficulties, and future directions of these new medicines. This work aims to present a thorough overview of the changing field of targeted therapeutics in hematologic oncology by analysing recent literature and clinical findings in-depth.

Section 1: Action Mechanisms

Hematologic malignancies treated with targeted treatments work by precisely interfering with particular molecular pathways that contribute to the development of cancer [1]. These treatments aim to minimise damage to healthy tissues while taking advantage of the unique vulnerabilities present in cancer cells. Comprehending the complex principles that underlie these focused therapies is essential to maximising their effectiveness and reducing their side effects.

Blocking of Deviant Signalling Routes

Inhibiting aberrant signalling pathways that promote malignant transformation and proliferation is one of the basic principles behind targeted treatments [2]. Tyrosine kinase inhibitors (TKIs) for chronic myeloid leukaemia (CML) include imatinib, dasatinib, and nilotinib, for example, suppress the activity of BCR-ABL, a constitutively active tyrosine kinase [3]. These inhibitors obstruct downstream signalling cascades essential for leukaemia cell survival and proliferation by selectively targeting the BCR-ABL fusion protein. Deep molecular responses and longer patient survival have resulted from this tailored intervention, which has completely changed the way CML is treated [4].

Analogously, drugs such as ibrutinib and idelalisib inhibit kinases including phosphatidylinositol 3-kinase (PI3K) delta and Bruce's tyrosine kinase (BTK) in B-cell lymphomas by targeting the B-cell receptor signalling pathway [5]. Through the disturbance of these pathways, these medicines hinder the proliferation and survival of B-cells, exhibiting noteworthy clinical effectiveness in a range of lymphoid malignancies.

Adjustment of Immune Reactions

By using the immune system to fight cancer cells, targeted immunotherapies have become a mainstay in the treatment of hematologic malignancies [6]. Targeting CD20 antigens on B-cell lymphomas, monoclonal antibodies like rituximab and obinutuzumab cause complement-mediated cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) [7]. By activating immune effector cells to identify and eradicate malignant B cells, these processes strengthen the body's innate immune response against the tumour.

Furthermore, immune checkpoint inhibitors, such as nivolumab and pembrolizumab, have shown promise in treating non-Hodgkin lymphoma subtypes and relapsed or refractory Hodgkin lymphoma [8]. These medicines restore T-cell-mediated antitumor immune responses by inhibiting immunological

checkpoints such as PD-1 (programmed cell death protein 1) or PD-L1 (programmed death-ligand 1), which in a fraction of patients results in tumour regression and sustained disease control.

Delivery of Cytotoxic Agents with Specificity

Delivering cytotoxic chemicals to cancer cells specifically reduces systemic toxicity, which is another tactic used in targeted therapy [9]. Antibody-drug conjugates (ADCs) are drugs that contain monoclonal antibodies and strong cytotoxic payloads, such brentuximab vedotin and inotuzumab ozogamicin. These antigen-binding cancer cell surface fragments (ADCs) connect to cancer cells precisely and transfer cytotoxic chemicals directly into the malignant cells, killing the cells while protecting healthy tissues [10].

Moreover, a novel method known as CAR-T cell treatment involves genetically modifying a patient's T cells to produce CARs, which are antigen-specific T cell receptors that are specific to antigens linked to tumours [11]. When infused into patients, CAR-T cells—such as axicabtagene ciloleucel and tisagenlecleucel—identify and eradicate cancer cells that express the target antigen. This results in long-lasting responses in certain hematologic malignancies, especially diffuse large B-cell lymphoma and relapsed/refractory B-cell acute lymphoblastic leukaemia.

To summarise, many strategies are utilised in targeted therapy for hematologic malignancies, such as immune response regulation, suppression of aberrant signalling pathways, and targeted administration of cytotoxic drugs. These approaches, which are distinguished by their decreased systemic toxicity and specificity, have fundamentally changed the way hematologic malignancies are treated and opened up new possibilities for better patient outcomes.

Section 2: Crucial Aims for Hematologic Cancers

For the purpose of developing efficient targeted therapeutics, it is essential to comprehend the primary targets in hematologic malignancies. These targets include dysregulated signalling pathways, overexpressed proteins, genetic mutations, and a variety of molecular changes that promote oncogenesis and act as focus sites for therapeutic treatments [1].

In Chronic Myeloid Leukaemia (CML), BCR-ABL

A defining genetic abnormality in CML is the BCR-ABL fusion gene, which is the product of the reciprocal translocation between chromosomes 9 and 22 [9, 22], sometimes referred to as the Philadelphia chromosome [2]. By constitutively activating the BCR-ABL tyrosine kinase, this fusion gene promotes the unchecked growth of myeloid cells [3]. Imatinib, dasatinib, and nilotinib are examples of targeted inhibitors that selectively decrease BCR-ABL's kinase activity, improving CML patients' prognosis and eliciting notable therapeutic responses [4].

B-cell malignancies and CD20

The surface antigen CD20, which is expressed on B cells, has become an important target in B-cell malignancies, such as NHL and CLL (chronic lymphocytic leukaemia) [5]. Monoclonal antibodies that particularly recognise and bind to CD20, such rituximab, ofatumumab, and obinutuzumab, cause complement-mediated cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) [6]. When it comes to B-cell malignancies, these tailored immunotherapies have greatly increased response rates and survival rates.

BTK in B-cell lymphomas and PI3K

Important signalling molecules in the B-cell receptor (BCR) pathway, Bruton's tyrosine kinase (BTK) and phosphatidylinositol 3-kinase (PI3K) delta, are involved in B-cell lymphomagenesis [7]. Inhibitors that target PI3K delta (idelalisib) and BTK (ibrutinib) have shown effectiveness in a variety of B-cell malignancies by interfering with signalling cascades that are crucial for B-cell survival and proliferation [8]. These drugs have demonstrated therapeutic effects, offering patients with relapsed or resistant diseases other course of treatment alternatives.

Mutations in IDH and FLT3 cause acute myeloid leukaemia (AML).

Genes encoding the enzymes isocitrate dehydrogenase (IDH) and FMS-like tyrosine kinase 3 (FLT3) have drawn interest as possible therapeutic targets in AML [9]. AML patients' poor prognosis and abnormal cell proliferation are caused by activating mutations in FLT3, namely FLT3-ITD (internal tandem duplication) and FLT3-TKD (tyrosine kinase domain) [10]. Midostaurin and gilteritinib, two targeted FLT3 inhibitors, have demonstrated effectiveness in enhancing the prognosis of AML patients with FLT3 mutations.

Similar to this, a subset of AML patients has mutations in IDH1 and IDH2, which result in the formation of 2-hydroxyglutarate (2-HG), an oncometabolite that promotes leukemogenesis [11]. IDH inhibitors preferentially target mutant IDH enzymes, such as enasidenib and ivosidenib. They have shown encouraging clinical outcomes and provide IDH-mutated AML patients a customised therapy strategy.

Section 3: Clinical Results and Difficulties

Enhanced Clinical Results

Significant advancements in the clinical outcomes of patients with hematologic malignancies have been predicted with the introduction of targeted treatments. In a variety of cancers, clinical studies and real-world data have repeatedly shown improved response rates, extended progression-free survival (PFS), and overall survival (OS).

Even in high-risk patients with del(17p) or TP53 mutations, the introduction of medicines such as ibrutinib and venetoclax has resulted in excellent response rates in chronic lymphocytic leukaemia (CLL) [1]. When used alone or in combination, these targeted therapies have greatly increased PFS and OS, providing CLL patients with long-lasting benefits and enhanced quality of life.

Tyrosine kinase inhibitors (TKIs) have also revolutionised the treatment of chronic myeloid leukaemia (CML), turning it into a chronic, controllable illness [2]. TKIs have shown significant rates of profound molecular responses, increasing treatment-free remission in certain CML patients and, in some cases, changing the paradigm of treatment from lifetime medication to cessation.

Furthermore, immunotherapeutic treatments have shown impressive success in treating refractory or recurrent Hodgkin and non-Hodgkin lymphomas, especially monoclonal antibodies and immune checkpoint inhibitors [3]. Patients with few treatment choices now have fresh hope because of the long-lasting responses observed in these cancers.

Obstacles and Restrictions

Targeted therapy for hematologic malignancies has several obstacles that impact their effectiveness and practical applicability, even with their noteworthy achievements.

Acquired Resistance: One major obstacle to long-term therapy success is resistance to targeted drugs. The development of second- or third-generation inhibitors is required for CML patients who, after early responses to TKIs, acquire resistance due to mutations in the BCR-ABL kinase domain or alternative signalling pathways [4].

Even with their increased selectivity, targeted medicines may yet have toxicities and off-target effects that result in unfavourable outcomes. BTK inhibitors, such as ibrutinib, for example, have been linked to elevated risk of bleeding, atrial fibrillation, and hypertension, which may affect treatment adherence and patient acceptability [5].

Heterogeneity of reactions: It might be difficult to determine which patients will benefit most from targeted medicines due to variation in patient reactions to them. In order to more accurately anticipate patient reactions and adjust medications accordingly, biomarker-driven techniques are essential [6].

Financial and Accessibility Issues: New targeted therapies may not be widely adopted due to cost or accessibility issues, particularly in areas with limited healthcare resources. This might have an influence on patients' ability to get these cutting-edge medicines [7].

Overcoming Obstacles and Prospective Views

Targeted treatment for hematologic malignancies is being attempted to address these obstacles using a variety of tactics:

Combination therapies: To increase efficacy and get around resistance mechanisms, various targeted drugs can be combined, or targeted therapies can be combined with more traditional treatments like immunotherapy or chemotherapy [8].

Biomarker Development: Molecular profiling and predictive biomarker discovery advances aid in patient classification, allowing for more accurate therapy selection and response tracking [9].

Novel Targets, Novel Drug Delivery Methods, and Next-Generation Inhibitors: Research on these topics is ongoing in an effort to create treatments that bypass resistance mechanisms, improve specificity, and minimise off-target consequences [10].

Access and Affordability: To guarantee equal access to these cutting-edge medications and close the affordability and accessibility gap, partnerships between pharmaceutical firms, governments, and healthcare organisations are crucial.

To sum up, patients with hematologic malignancies now have significantly better clinical outcomes because to targeted therapy. To fully realise the potential of these medicines, however, obstacles including acquired resistance, off-target effects, heterogeneity of responses, and access concerns must be resolved. Future targeted therapy in hematologic oncology may be shaped by cooperative efforts, creative thinking, and ongoing research to overcome these obstacles.

Section 4: New Approaches to Treatment

T-cell therapy using chimeric antigen receptors (CARs)

A novel strategy for the treatment of hematologic malignancies, especially B-cell malignancies, is chimeric antigen receptor (CAR) T-cell therapy [1]. Through genetic alteration, a patient's T cells are used in CAR-T treatment to express synthetic receptors (CARs) that specifically target antigens on tumour cells.

Success in Diffuse Large B-Cell Lymphoma (DLBCL) and B-Cell Acute Lymphoblastic Leukaemia (B-ALL): CAR-T treatments, such tisagenlecleucel and axicabtagene ciloleucel, have shown amazing results in DLBCL and B-ALL that are resistant or have relapsed [2]. After receiving CAR-T therapy, patients who had run out of choices for traditional treatment obtained long-lasting remissions.

Extension of Use: By targeting distinct antigens or combining CAR-T cells with other treatment modalities, ongoing research attempts to extend the usefulness of CAR-T therapy to additional hematologic malignancies and solid tumours [3].

ADCs, or antibody-drug conjugates

Combining the cytotoxic efficacy of chemotherapy with the specificity of monoclonal antibodies, antibody-drug conjugates (ADCs) are a potential class of targeted therapeutics [4]. These ADCs enable the targeted delivery of the cytotoxic payload to tumour cells since they are made up of monoclonal antibodies coupled to strong cytotoxic chemicals.

Achievements in Lymphoma and Leukaemias: ADCs targeting CD30 in Hodgkin lymphoma and anaplastic large-cell lymphoma, such as benuximab vedotin, have shown remarkable clinical success [5]. Promising outcomes have also been observed with inotuzumab ozogamicin, which targets CD22 in B-cell acute lymphoblastic leukaemia.

Developments and New ADCs: In an effort to increase the number of efficient targeted treatments available, current research is concentrated on creating new ADCs with better payloads, increased specificity, and less off-target effects [6].

Minimal Molecule Deterrents

The arsenal of targeted treatments for hematologic malignancies has grown as a result of ongoing developments in small molecule inhibitors [7]. These inhibitors specifically target enzymes or kinases that are part of oncogenic signalling cascades.

BTK and PI3K Inhibitors: By interfering with vital signalling pathways, idelalisib, which targets PI3K delta, and ibrutinib, which targets BTK, have completely changed the way that B-cell malignancies are treated [8]. New inhibitors of BTK and PI3K are being developed to improve effectiveness and lessen side effects.

Selective Inhibition and Resistance Management: Next-generation inhibitors are made to be more powerful and selective than their predecessors, with the goal of overcoming resistance mechanisms [9].

Cell-based treatments and innovative immunotherapies

Novel immunotherapies and cell-based treatments, in addition to CAR-T cell therapy, are still developing and providing new treatment options for hematologic malignancies [10].

NK Cell treatments: Research is being done on NK cell treatments as a possible therapy for hematologic malignancies. These therapies use the innate immune response to target cancer cells [11]. To improve NK cells' ability to target tumours and remain persistent, research is still being done.

Combination therapy combining chimeric antigen receptor natural killer (CARTNK) cells and bispecific antibodies are being investigated as a means of combining the benefits of antibody- and cell-based treatment for hematologic malignancies [12].

Final Thoughts and Upcoming Prospects

The field of targeted therapeutics for hematologic malignancies is still developing quickly, and new approaches have the potential to overcome current obstacles and enhance patient outcomes. Innovative techniques such as CAR-T cell therapy, ADCs, small molecule inhibitors, and new immunotherapies have shown great effectiveness in treating a variety of hematologic malignancies.

The field's future prospects include improving already available treatments, extending their suitability to a wider range of cancers, reducing side effects, controlling resistance, and creating combination plans that work in concert to maximise therapy effectiveness.

The translation of these innovative therapeutic approaches from bench to bedside—and eventually the provision of more efficient and customised therapy options for patients with hematologic malignancies—requires close collaborations between researchers, physicians, and pharmaceutical corporations.

CONCLUSION AND FUTURE DIRECTIONS

Progress in the Field of Precision Medicine

Precision medicine is the key to the future of tailored therapy for hematologic malignancies. Precision medicine seeks to maximise therapeutic efficacy while minimising side effects by customising care based on each patient's unique molecular and genetic makeup [1].

Genomic Profiling and Biomarker Discovery: Combining biomarker discovery with cutting-edge genomic technology has enormous potential for finding new targets and forecasting therapeutic outcomes. Selecting targeted therapy is made easier by the discovery of actionable mutations made possible by comprehensive molecular profiling [2].

Liquid Biopsies and Real-Time Monitoring: Non-invasive techniques for tracking the course of a disease, spotting minimal residual illness, and figuring out new resistance mechanisms are made possible by liquid biopsies, such as circulating tumour DNA (ctDNA) analysis. Timely modifications to treatment plans are made possible by real-time monitoring [3].

Getting Past Resistance and Increasing Effectiveness

In hematologic oncology, addressing resistance mechanisms and improving the effectiveness of targeted medicines continue to be important areas of attention.

Combination therapies and rational drug design: To overcome resistance and improve synergistic effects, targeted drugs, immunotherapies, and conventional treatments are strategically combined. The process of developing treatments that target numerous pathways at once in order to stop or postpone resistance processes is known as rational drug design [4].

Personalised medicine and adaptive clinical trial designs: Biomarker-driven tactics in adaptive clinical trial designs help to identify patient subgroups who are likely to benefit, speed up the evaluation of new medicines, and support the creation of personalised treatment plans [5].

New Technologies and Creative Methodologies

Innovative methods and technological developments are about to completely change the field of targeted therapy for hematologic malignancies.

Gene editing and gene therapies: Recent developments in CRISPR-Cas9 and other gene editing technologies provide opportunities for precise alterations in cancer cells, which may fix genetic defects or improve the effectiveness of immunotherapies [6]. Preclinical and early clinical investigations on gene treatments, which include introducing therapeutic genes into malignant cells, continue to demonstrate promise.

Predictive modelling and Artificial Intelligence: Data analysis, predictive modelling, and the detection of treatment response patterns are made easier by the combination of machine learning algorithms with artificial intelligence (AI). Based on intricate datasets, AI-driven algorithms assist in the identification of possible therapy targets and the forecasting of patient outcomes [7].

In conclusion, the path towards customised and inventive treatments

In summary, the field of targeted therapy for hematologic malignancies is rapidly changing due to new discoveries about the molecular causes of cancer and creative treatment strategies. A paradigm shift in cancer care is indicated by the move towards accurate and customised treatments, underscoring the significance of customised therapy.

Future directions for targeted medicines are interdisciplinary and will involve researchers, doctors, pharmaceutical companies, and regulatory authorities working together. To fully realise the potential of targeted therapeutics in hematologic cancer, it is imperative to use state-of-the-art technology, optimise clinical trial designs, and translate research findings into clinical practice.

The future is bright for patients with hematologic malignancies as long as new targets are consistently explored, current medicines are improved, and personalised medicine is incorporated into clinical practice.

REFERENCES

1. Crisci, S., Amitrano, F., Saggese, M., Muto, T., Sarno, S., Mele, S., ... & Di Francia, R. (2019). Overview of current targeted anti-cancer drugs for therapy in onco-hematology. *Medicina*, *55*(8), 414.
2. Tallman, M. S. (2002, October). Advancing the treatment of hematologic malignancies through the development of targeted interventions. In *Seminars in hematology* (Vol. 39, No. 4, pp. 1-5). WB Saunders.
3. Shimada, A. (2019). Hematological malignancies and molecular targeting therapy. *European journal of pharmacology*, *862*, 172641.
4. Sochacka-Ćwikła, A., Mączyński, M., & Regiec, A. (2021). FDA-approved drugs for hematological malignancies—The last decade review. *Cancers*, *14*(1), 87.
5. Podhorecka, M., Markowicz, J., Szymczyk, A., & Pawlowski, J. (2014). Target therapy in hematological malignances: new monoclonal antibodies. *International scholarly research notices*, *2014*.

6. Shukry, S., Hariri, F., & Al-Nehmi, A. W. (2019). Target therapy in hematological malignancies. *Advances in Hematologic Malignancies*, 119.
7. Noh, J. Y., Seo, H., Lee, J., & Jung, H. (2020). Immunotherapy in hematologic malignancies: Emerging therapies and novel approaches. *International journal of molecular sciences*, *21*(21), 8000.
8. Piccaluga, P. P., Martinelli, G., & Baccarani, M. (2006). Advances in the treatment for haematological malignancies. *Expert opinion on pharmacotherapy*, *7*(6), 721-732.
9. Gallipoli, P., & Huntly, B. J. (2018, August). Novel epigenetic therapies in hematological malignancies: current status and beyond. In *Seminars in Cancer Biology* (Vol. 51, pp. 198-210). Academic Press.
10. Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., ... & Yang, S. (2021). Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives. *Signal transduction and targeted therapy*, *6*(1), 201.
11. Wang, L., Qin, W., Huo, Y. J., Li, X., Shi, Q., Rasko, J. E., ... & Zhao, W. L. (2020). Advances in targeted therapy for malignant lymphoma. *Signal transduction and targeted therapy*, *5*(1), 15.